参考文献/References:
[1] Goodacre S,Cross E,Arnold J,et al. The health care burden of acute chest pain[J]. Heart,2005,91(2):229-230.
[2] Roffi M,Patrono C,Collet JP,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2016,37(3):267-315.
[3] Bandstein N,Wikman A,Ljung R,et al. Survival and resource utilization in patients with chest pain evaluated with cardiac troponin T compared with high-sensitivity cardiac troponin T[J]. Int J Cardiol,2017,245:43-48.
[4] Collet JP,Thiele H,Barbato E,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J,2020,Aug 29;ehaa575.?DOI: 10.1093/eurheartj/ehaa575.?Online ahead of print.
[5] Apple FS,Sandoval Y,Jaffe AS,et al. Cardiac troponin assays: guide to understanding analytical characteristics and their impact on clinical care[J]. Clin Chem,2017,63(1):73-81.
[6] Apple FS. A new season for cardiac troponin assays:it’s time to keep a scorecard[J]. Clin Chem,2009,55(7):1303-1306.
[7] Hallén J. Troponin for the estimation of infarct size:what have we learned?[J]. Cardiology,2012,121(3):204-212.
[8] Ibanez B,James S,Agewall S,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2018,39(2):119-177.
[9] Amsterdam EA,Wenger NK,Brindis RG,et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2014,64(24):e139-e228.
[10] Mueller C,Giannitsis E,Christ M,et al. Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac troponin T[J]. Ann Emerg Med,2016,68(1):76-87.e74.
[11] Twerenbold R,Neumann JT,S?rensen NA,et al. Prospective validation of the 0/1-h algorithm for early diagnosis of myocardial infarction[J]. J Am Coll Cardiol,2018,72(6):620-632.
[12] Badertscher P,Boeddinghaus J,Twerenbold R,et al. Direct comparison of the 0/1h and 0/3h algorithms for early rule-out of acute myocardial infarction[J]. Circulation,2018,137(23):2536-2538.
[13] Body R. Acute coronary syndromes diagnosis,version 2.0:Tomorrow’s approach to diagnosing acute coronary syndromes?[J]. Turk J Emerg Med,2018,18(3):94-99.
[14] Pickering JW,Than MP, Cullen L,et al. Rapid rule-out of acute myocardial infarction with a single high-sensitivity cardiac troponin T measurement below the limit of detection:a collaborative meta-analysis[J]. Ann Intern Med,2017,166(10):715-724.
[15] Rubini Gimenez M,Twerenbold R,Reichlin T,et al. Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction[J]. Eur Heart J,2014,35(34):2303-2311.
[16] Haaf P,Reichlin T,Twerenbold R,et al. Risk stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays[J]. Eur Heart J,2014,35(6):365-375.
[17] Mark DG,Huang J,Chettipally U,et al. Performance of coronary risk scores among?patients with chest pain in the emergency department[J]. J Am Coll Cardiol,2018,71(6):606-616.
[18] Mahler SA,Riley RF,Hiestand BC,et al. The HEART Pathway randomized trial:identifying emergency department patients with acute chest pain for early discharge[J]. Circ Cardiovasc Qual Outcomes,2015,8(2):195-203.
[19] Bohula May EA,Bonaca MP,Jarolim P,et al. Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome[J]. Clin Chem,2014,60(1):158-164.
[20] Reichlin T,Schindler C,Drexler B,et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T[J]. Arch Intern Med,2012,172(16):1211-1218.
[21] 高文君. 急性冠脉综合征预后的预测研究进展[J]. 心血管病学进展,2018,39(4):606-610.
[22] Blankenberg S,Salomaa V,Makarova N,et al. Troponin I and cardiovascular risk prediction in the general population:the BiomarCaRE consortium[J]. Eur Heart J,2016,37(30):2428-2437.
[23] Apple FS,Steffen LM,Pearce LA,et al. Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death:the Minnesota Heart Survey[J]. Clin Chem,2012,58(5):930-935.
[24] Ford I,Shah AS,Zhang R,et al. High-sensitivity cardiac troponin,statin?therapy,and risk of coronary?heart?disease[J]. J Am Coll Cardiol,2016,68(25):2719-2728.
[25] Xiao W,Cao R,Liu Y,et al. Association of high-sensitivity cardiac troponin T with mortality and cardiovascular events in a community-based prospective study in Beijing[J]. BMJ Open,2017,7(6):e013431.
[26] Samman Tahhan A,Sandesara P,Hayek SS,et al. High-sensitivity troponin I levels and coronary artery disease severity, progression, and long-term outcomes[J]. J Am Heart Assoc,2018,7(5):e007914.
[27] Anand A,Shah ASV,Beshiri A,et al. Global adoption of high-sensitivity cardiac troponins and the universal definition of myocardial infarction[J]. Clin Chem,2019,65(3):484-489.
[28] Januzzi JL Jr,Mahler SA,Christenson RH,et al. Recommendations for institutions transitioning to high-sensitivity troponin testing:JACC?Scientific Expert Panel[J]. J Am Coll Cardiol,2019,73(9):1059-1077.
[29] Giannitsis E,Katus HA. Cardiac troponin level elevations not related to acute coronary syndromes[J]. Nat Rev Cardiol,2013,10(11):623-634.
[30] Sherwood MW,Kristin Newby L. High-sensitivity troponin assays:evidence,indications,and reasonable use[J]. J Am Heart Assoc,2014,3(1):e000403.
[31] Wu AH,Lu QA,Todd J,et al. Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay:implications for clinical practice[J]. Clin Chem,2009,55(1):52-58.
[32] Vasile VC,Saenger AK,Kroning JM,et al. Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay[J]. Clin Chem,2010,56(7):1086-1090.
[33] Twerenbold R,Jaeger C,Rubini Gimenez M,et al. Impact of high-sensitivity cardiac troponin on use of coronary angiography,cardiac stress testing,and time to discharge in suspected acute myocardial infarction[J]. Eur Heart J,2016,37(44):3324-3332.
相似文献/References:
[1]李润土,何泉.光学相干断层成像在急性冠脉综合征介入治疗中的应用[J].心血管病学进展,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
LI Runtu,HE Quan.Application of Optical Coherent Tomography in Interventional Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(5):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
[2]郑晓雪 季福绥.急性冠脉综合征患者发生急性肾损伤的临床进展[J].心血管病学进展,2019,(5):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
ZHENG Xiaoxue,JI Fusui.Acute Kidney Injury in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(5):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
[3]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[4]吕俊兴 许海燕.急性冠脉综合征危险评分的研究进展[J].心血管病学进展,2019,(9):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
LU Junxing,XU Haiyan.Risk Scores of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(5):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
[5]吕颖 胡思宁 于波 贾海波.斑块侵蚀发病机制的最新研究进展[J].心血管病学进展,2020,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
LU Ying,HU Sining,YU Bo,et al.Pathogenic Mechanisms of Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(5):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
[6]段继坤,林志,杨帆,等.斑块侵蚀引起的急性冠脉综合征的研究新进展[J].心血管病学进展,2020,(3):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
DUAN Jikun,LIN Zhi,YANG Fan,et al.Acute Coronary Syndrome Caused by Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(5):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
[7]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(5):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[8]肖雨尘 赵仙先 马丽萍.急性冠脉综合征患者提前停服替格瑞洛现象的研究进展[J].心血管病学进展,2020,(11):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
Acute Coronary Syndrome.Premature Ticagrelor Discontinuation in Patients with[J].Advances in Cardiovascular Diseases,2020,(5):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[9]冯洁渊 .中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值与急性冠脉综合征的关系研究进展[J].心血管病学进展,2020,(12):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
FENG Jieyuan.The Relationship Between Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio and Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2020,(5):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
[10]朱志伦 田乃亮.急性冠脉综合征患者抗血小板降阶治疗方案研究进展[J].心血管病学进展,2021,(6):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
ZHU Zhilun,TIAN Nailiang.Advances in De-Escalation of Anti-Platelet Therapy in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(5):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]